#USA #New York #Securities Law #Faruqi & Faruqi #Gossamer Bio

Gossamer Bio Investors on Alert for Class Action Deadline

Gossamer Bio, Inc. (NASDAQ: GOSS) is currently under scrutiny as Faruqi & Faruqi, LLP, a prominent national securities law firm, reminds investors of an important deadline approaching on June 1, 2026. This is the final date for those who purchased Gossamer stocks between June 16, 2025, and February 20, 2026, to seek the role of lead plaintiff in a federal securities class action filed against the company.

Summary of the Allegations

The lawsuit stems from the claims that Gossamer Bio and its executive team misled investors regarding the design and results of their Phase 3 PROSERA clinical study. The study, which aimed to evaluate improvements in six-minute walk distance (6MWD), reported negative topline results on February 23, 2026, failing to meet its primary endpoint. This failure raised questions about the reliability of the study when it was announced that the placebo response was unexpectedly strong among participants at Latin American sites, which the company categorized as a lower-risk population.

Upon this announcement, Gossamer's stock price suffered a dramatic drop from $2.13 on February 20 to just $0.42 by the close of the trading day—an astonishing decline of over 80%. Investors reacted swiftly to the news, reflecting the market's concern over the company's handling of crucial information.

Taking Action as an Investor

According to Faruqi & Faruqi, the leader of a securities class action is generally the investor with the largest financial interest that also meets the typicality and adequacy standards of the plaintiff class. Affected parties have the option to either apply for lead plaintiff status or remain an absent class member, with no impact on potential recovery from the lawsuit based on that choice. The firm strongly encourages former employees, whistleblowers, and any individuals with potentially relevant information to come forward to support the investigation.

Contact Information

For those who may have been affected and are seeking to discuss their legal rights or want further details on the class action, they can contact Faruqi & Faruqi’s partner, Josh Wilson, directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Additional information can also be found on the firm’s website at www.faruqilaw.com/GOSS.

This unfolding situation serves as a reminder of the importance of transparency in clinical trials and the obligation of companies to communicate accurately with their investors. As the deadline approaches, investors should remain vigilant and take proactive measures.